miR-15b represses BACE1 expression in sporadic Alzheimer’s disease

Guohua Gong; Fengmao An; Yu Wang; Ming Bian; Li-Jun Yu; Chengxi Wei

doi:10.18632/oncotarget.21177

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression of Concern

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

miR-15b represses BACE1 expression in sporadic Alzheimer’s disease

Guohua Gong, Fengmao An, Yu Wang, Ming Bian, Li-Jun Yu and Chengxi Wei _

PDF | HTML | How to cite

Oncotarget. 2017; 8:91551-91557. https://doi.org/10.18632/oncotarget.21177

Metrics: PDF 1696 views | HTML 2370 views | ?

Abstract

Guohua Gong1,2,3,*, Fengmao An1,2,*, Yu Wang1,2, Ming Bian1,2, Li-Jun Yu1,2 and Chengxi Wei1,2

1Medicinal Chemistry and Pharmacology Institute, Inner Mongolia University for The Nationalities, Tongliao, Inner Mongolia, P.R. China

2Inner Mongolia Key Laboratory of Mongolian Medicine Pharmacology for Cardio-Cerebral Vascular System, Tongliao, Inner Mongolia, P.R. China

3First Clinical Medical of Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Chengxi Wei, email: [email protected]

Li-Jun Yu, email: [email protected]

Keywords: alzheimer’s disease, miR-15b, BACE1, cell viability, cell apoptosis

Received: June 01, 2017 Accepted: August 06, 2017 Published: September 21, 2017

ABSTRACT

Beta-site Amyloid precursor protein Cleaving Enzyme 1 (BACE1) is conceived as a potential target for therapies against Alzheimer disease (AD). MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression in a sequence-specific manner. Although miRNAs have been increasingly recognized as important modulators in sporadic AD. In order to confirm whether miR-15b correlates with the BACE1 upregulation in sporadic AD, we firstly evaluated the expression of miR-15b and BACE1 in sporadic AD brain tissues and analyzed the correlation of miR-15b with BACE1. Then we determined the regulation of miR-15b in SH-SY5Y cells on the BACE1 expression. And finally we determined the targeting to 3’ UTR of BACE1 by miR-15b by a luciferase reporter. Downregulation of miR-15b alleviated Aβ-induced viability inhibition and decreased apoptosis in SH-SY5Y cells. Our results demonstrated that miR-15b play an important role in the cellular AD phenotype and might be involved in the pathogenesis of AD.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21177

Publication Alerts

Research Papers:

miR-15b represses BACE1 expression in sporadic Alzheimer’s disease

Abstract